Our work establishes the IL-4 mediated cancer cell TAP2 downregulation as a novel, dominant and potentially actionable mechanism of T-cell immune evasion and immunotherapy resistance in human NSCLC and elucidates the mechanism mediating these responses with broad biological and potential clinical implications. This evidence concerns the gene TAP2 and cancer.